Eli Lilly and Company (NYSE:LLY) Price Target Increased to $1,250.00 by Analysts at Citigroup

Eli Lilly and Company (NYSE:LLY) had its price target hoisted by Citigroup from $1,060.00 to $1,250.00 in a research note issued to investors on Friday morning, Benzinga reports. Citigroup currently has a buy rating on the stock.

LLY has been the subject of several other reports. Barclays upped their target price on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. Guggenheim lifted their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $1,025.00 price target on shares of Eli Lilly and Company in a research report on Thursday, October 3rd. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Finally, Bank of America raised their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,013.41.

Eli Lilly and Company Trading Up 0.3 %

NYSE LLY opened at $895.71 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The business has a fifty day simple moving average of $919.22 and a 200 day simple moving average of $864.16. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The firm has a market capitalization of $851.29 billion, a P/E ratio of 131.92, a PEG ratio of 3.24 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. On average, analysts predict that Eli Lilly and Company will post 14.05 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.58%. Eli Lilly and Company’s payout ratio is 76.58%.

Institutional Trading of Eli Lilly and Company

Hedge funds and other institutional investors have recently bought and sold shares of the company. Lynx Investment Advisory bought a new position in shares of Eli Lilly and Company in the second quarter worth $32,000. LGT Financial Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at about $36,000. Redmont Wealth Advisors LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter valued at about $40,000. Morton Brown Family Wealth LLC grew its holdings in shares of Eli Lilly and Company by 45.5% during the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after purchasing an additional 15 shares in the last quarter. Finally, Cedar Mountain Advisors LLC increased its position in shares of Eli Lilly and Company by 53.3% in the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock worth $41,000 after purchasing an additional 16 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.